The Quantellect read.As of Nov 19, 2026, 4 active firms cover CareDx Inc: 2 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $21.00 to $80.00 (about 3.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $55.25 sits 26% below the current $74.34. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.31 next quarter toward $1.56 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy250%
Neutral250%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$55.25
-25.7% downside
Average target across 4 active firms as of Nov 19, 2026 vs $74.34 current
Highest Target$80.00
Average Target$55.25
Lowest Target$21.00
Detailed analyst forecasts for CDNA
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 2 of 4 active firms rate CDNA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CDNA EPS & revenue forecast
EPS · NEXT QUARTER
$0.31
Range $0.24 – $0.37 · 7 analysts · -9% YoY
Next period, 7 analysts expect CareDx Inc to earn $0.31 a share (range $0.24 – $0.37), versus $0.34 a year earlier. Full-year consensus is $1.78, growing to $1.56 the year after.
REVENUE · NEXT QUARTER
$130.9M
Range $127.8M – $133.7M · 7 analysts · +11% YoY
Revenue is expected to reach $130.9M (range $127.8M – $133.7M), +11.2% year-over-year. Full-year consensus is $524.8M, rising to $572.0M next year.
Top analysts covering CareDx Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CDNA.
#1
MC
Mason Carrico
Stephens & Co. · Rank #178
Buy
$40.00-46.2% to target
Overall win rate
40%
+ Follow
#2
KM
Kyle Mikson
Canaccord Genuity · Rank #202
Buy
$80.00+7.6% to target
Overall win rate
40%
+ Follow
#3
Mark Massaro
BTIG · Rank #220
Buy
$74.00-0.5% to target
Overall win rate
44%
+ Follow
#4
Yi Chen
HC Wainwright & Co. · Rank #350
Neutral
$46.00-38.1% to target
Overall win rate
34%
+ Follow
#5
Matthew Sykes
Goldman Sachs · Rank #352
Buy
$26.00-65.0% to target
Overall win rate
38%
+ Follow
CDNA stock forecast FAQ
What is CDNA's average 12-month price target?+
The 4 active firms with a live target average $55.25 for CareDx Inc over the next 12 months, ranging from a $80.00 high to a $21.00 low, as of Nov 19, 2026.
Is CDNA stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CDNA?+
The Street-high target is $80.00 (Canaccord Genuity), and the Street-low is $21.00 (Wells Fargo). The average of all 4 active-firm targets is $55.25.
How many active Wall Street firms cover CDNA?+
4 active firms have a recognized rating on CareDx Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CDNA?+
Among analysts who currently cover CDNA, Mason Carrico of Stephens & Co. has the strongest overall Quantellect track record (Rank #178). Their current call is Buy with a $40.00 target.
What is CareDx Inc's projected EPS for next quarter?+
The consensus estimate is $0.31 per share (range $0.24 – $0.37) across 7 analysts. Full-year EPS is projected at $1.78, rising to $1.56 the following year.
How much revenue is CareDx Inc expected to report next quarter?+
Consensus revenue is $130.9M (range $127.8M – $133.7M). Full-year revenue is projected at $524.8M, growing to $572.0M next year.
Have analysts been upgrading or downgrading CDNA lately?+
As of Nov 19, 2026, 2 of 4 active firms rate CDNA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CDNA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.